Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Cell membrane |
Domain | - |
Function |
Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis. |
Biological Process |
GO:0030522 intracellular receptor signaling pathway GO:0048384 retinoic acid receptor signaling pathway GO:0048385 regulation of retinoic acid receptor signaling pathway GO:0048387 negative regulation of retinoic acid receptor signaling pathway |
Molecular Function |
GO:0008134 transcription factor binding GO:0035257 nuclear hormone receptor binding GO:0042974 retinoic acid receptor binding GO:0051427 hormone receptor binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PRAME and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between PRAME and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PRAME in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PRAME in various data sets.
|
Points in the above scatter plot represent the mutation difference of PRAME in various data sets.
|
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRAME. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRAME. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRAME. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRAME. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PRAME expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PRAME and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PRAME |
Name | preferentially expressed antigen in melanoma |
Aliases | CT130; cancer/testis antigen 130; MAPE; OIP-4; OIP4; Opa-interacting protein OIP4; opa-interacting protein 4 ...... |
Chromosomal Location | 22q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PRAME collected from DrugBank database. |
There is no record. |